INVENTIVA: Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing
Inventiva said it completed key steps of a combined EIB and new debt financing transaction on June 12, 2026. It prepaid EIB loans of about €62.2m and repurchased/cancelled EIB warrants for €50m (including 700,000 Tranche B warrants). It issued Tranche A convertible bonds (€35m) and Tranche B amortized bonds (€40m) for €71.3m net proceeds, with conversion price €5.2893 and lender warrant exercise price €4.1559.
Deleveraging plus new secured convertible/amortized debt changes near-term capital structure and introduces dilution/optionality via conversion and warrants.
Inventiva completed repayment of €62.2m EIB loans, repurchased EIB warrants for €50m, and issued €75m Tranche A/B debt with set conversion/exercise prices.
Likely near-term volatility around dilution/financing overhang, with potential support if traders view the financing as extending runway and removing EIB overhang.
Background
Inventiva previously announced a combined transaction (EIB loan repayment/warrant repurchase plus new debt tranches) contingent on completing an equity financing of at least €90m.
Why it matters
The company reports completion of the EIB settlement and issuance of the first two debt tranches, with explicit conversion ratio and lender warrant exercise price, effectively locking in the capital-structure changes.
Market relevance
Traders can update financing/dilution expectations using the disclosed €75m debt issuance, €62.2m EIB loan payoff, and the specific €5.2893 conversion price and €4.1559 warrant exercise price.
Market effects
Biopharma financing via EIB + convertible/amortized tranches signals continued reliance on structured capital to fund late-stage trials; may affect read-across for other clinical-stage issuers’ financing terms.
Supports sentiment for Euronext/Nasdaq-listed small/mid-cap biotechs completing structured financings.
Limited beyond structured-debt/convertible market participants tracking conversion/warrant pricing and secured lender terms.
Alternative perspectives
The conversion price and warrant exercise price are set at premiums to the equity offering price, which could reduce immediate dilution pressure versus lower-priced deals.
Remaining EIB warrants require shareholder approval for cancellation; timing of the June 30, 2026 general meeting could create additional event risk/volatility.
Key entities
- companyInventiva
Clinical-stage biopharma focused on oral therapy for MASH; completed EIB repayment/warrant repurchase and issued Tranche A/B debt.
- lenderEuropean Investment Bank (EIB)
Provided loans and warrants that were prepaid/repurchased as part of the transaction.
- lendersBlackRock and Claret Capital Partners
Managed funds/accounts that subscribed to the debt tranches and received lender warrants.
